{
  "docId": "019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "docSlug": "7a45cce2c7eb1605e2a52f1d1ebe6b6d",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 20 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 20,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "business_model",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-bf16-778d-9d2b-a6c6e17ebc6c/12",
  "deckHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "deckJsonHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c.json",
  "deckAnchorHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.24,
        "x": 0.45,
        "y": 0.349
      },
      "kind": "callout",
      "text": "While pre-commercial revenues are comparable, commercial revenues can vary significantly",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa106076-e719-4dd4-b9f4-38241795b53b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.43,
        "x": 0.28,
        "y": 0.193
      },
      "kind": "chart",
      "text": "Example Partnerships NPV*\n~$165M\n$147\n$18\n~$53M\n$37\n$16\n~$85M\n$69\n$16\nHigher Value Partnership\nWeighted Average NPV**\nPre-Commercial\nCommercial",
      "attrs": {
        "chart_type": "stacked bar"
      },
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66723188-a2a5-4652-8164-5bf95e43d569",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.049,
        "w": 0.179,
        "x": 0.037,
        "y": 0.87
      },
      "kind": "image",
      "text": "MaxCyte",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08d8b617-850b-411b-a70d-bffd74732e0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.316,
        "w": 0.229,
        "x": 0.048,
        "y": 0.268
      },
      "kind": "list",
      "text": "Higher Value Partnership NPV\nInfluencing Factors:\nLarge indications – greater royalty revenues or early achievement of sales-based milestones\nInstrument & consumables – Higher utilization",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab6b0b16-bd39-4ecc-9ac9-582842cced78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.24,
        "x": 0.72,
        "y": 0.268
      },
      "kind": "list",
      "text": "Lower Value Partnership NPV\nInfluencing Factors:\nSmall indications – lower sales royalties or longer time period to realize commercial milestones\nConservative commercial milestones – Smaller opportunity\nInstrument & consumables – Lower utilization",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec3e987c-9182-4989-b485-7b42b0439b91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.354,
        "x": 0.323,
        "y": 0.248
      },
      "kind": "other",
      "text": "Assumes 6 programs per SPL launching 1 year apart, 2 fail in preclinical, 4 enter clinical, and 1 reaches commercial",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "200e2624-c07d-4eb9-900f-ebf31388e0fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.28,
        "x": 0.365,
        "y": 0.899
      },
      "kind": "source-note",
      "text": "Numbers are illustrative as an example and not specific to one SPL Partnership",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3230575e-4ba1-4763-b70d-6a64732dce44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.23,
        "x": 0.048,
        "y": 0.77
      },
      "kind": "source-note",
      "text": "*10-year NPV\n**Weighted based on the expected split of commercial programs in Year 6 (assuming earliest approval); Assumes first 5-years of standard ten-year biotech sales curve",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dbc5459-377d-4028-80ed-ed28cf885f80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.029,
        "w": 0.899,
        "x": 0.042,
        "y": 0.07
      },
      "kind": "title",
      "text": "SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2210b1ff-21a3-4e84-b7dc-ff98e288f1d2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b37bf2a-4731-4886-81e1-dbaaf7521786",
      "evidence": "The deck presents the benefits of MaxCyte's technology and the limitations of current methods.",
      "position": 0,
      "objective": "What are the consequences of not adopting MaxCyte's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 13,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "aef0ad90-31bd-4c88-a7ab-1edcbad173d9",
      "evidence": "The deck presents information on SPL partnerships and revenue potential.",
      "position": 1,
      "objective": "What are the potential revenue upsides from SPL partnerships?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}